Insulet Corporation (PODD)
Insulet (NASDAQ:PODD) Sets New 52-Week Low – Here’s Why
Insulet Corporation (NASDAQ: PODD - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Friday. The company traded as low as $220.28 and last traded at $226.71, with a volume of 300006 shares traded. The stock had previously closed at $236.07. Key Headlines Impacting Insulet Here are the key news
Insulet Corporation (NASDAQ:PODD) Sees Significant Increase in Short Interest
Insulet Corporation (NASDAQ: PODD - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 2,817,783 shares, an increase of 86.4% from the February 12th total of 1,511,612 shares. Based on an average daily volume of 1,172,256 shares, the
Insulet recalls some insulin devices in US over leakage risk
Insulet has recalled specific batches of its insulin-delivery pods in the U.S. after finding a manufacturing defect that could stop diabetic users from getting their full dose of the blood sugar-regulating hormone, the medical device maker said on Thursday.
Insulet: The Growth Doesn't Stop Here
The market is overstating the impact of GLP-1s and fails to recognize that GLP-1s pose no direct threat to Insulet's customer base. International expansion into Europe (the largest addressable market for T1D) and the shift into MENA focus will drive top-line growth. The T2D market is underpenetrated, representing a wide potential runway, from which PODD is set to win the most based on structural moats.
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.15 per share a year ago.
Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is PODD A Better Bet Than ISRG Stock?
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
